Nktr-KO 基因敲除小鼠

1. Srinagesh, Hrishikesh, Jackson, Clayton, Shiraz, Parveen, Mackall, Crystal, Muffly, Lori. . A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia. In Blood, 144, 1689-1698. doi:10.1182/blood.2024024952. https://pubmed.ncbi.nlm.nih.gov/38968138/

2. Miyazaki, Takahiro, Maiti, Mekhala, Hennessy, Marlene, Kivimäe, Saul, Zalevsky, Jonathan. . NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy. In Journal for immunotherapy of cancer, 9, . doi:10.1136/jitc-2020-002024. https://pubmed.ncbi.nlm.nih.gov/34001523/

3. Doberstein, Stephen K. 2019. Bempegaldesleukin (NKTR-214): a CD-122-biased IL-2 receptor agonist for cancer immunotherapy. In Expert opinion on biological therapy, 19, 1223-1228. doi:10.1080/14712598.2019.1685489. https://pubmed.ncbi.nlm.nih.gov/31652082/

4. Robinson, Tanya O, Hegde, Shweta M, Chang, Allison, Miyazaki, Takahiro, Schluns, Kimberly S. . NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells. In The Journal of clinical investigation, 131, . doi:10.1172/JCI144365. https://pubmed.ncbi.nlm.nih.gov/34375310/

5. Dixit, Neha, Fanton, Christie, Langowski, John L, Doberstein, Stephen K, Zalevsky, Jonathan. 2021. NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. In Journal of translational autoimmunity, 4, 100103. doi:10.1016/j.jtauto.2021.100103. https://pubmed.ncbi.nlm.nih.gov/34041473/

6. Adkins, Chris E, Nounou, Mohamed I, Hye, Tanvirul, Hoch, Ute, Lockman, Paul R. 2015. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. In BMC cancer, 15, 685. doi:10.1186/s12885-015-1672-4. https://pubmed.ncbi.nlm.nih.gov/26463521/

7. Walker, Joshua M, Rolig, Annah S, Charych, Deborah H, Hilgart-Martiszus, Ian F, Redmond, William L. . NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer. In Journal for immunotherapy of cancer, 8, . doi:10.1136/jitc-2019-000464. https://pubmed.ncbi.nlm.nih.gov/32457127/

8. Kopruszinski, Caroline M, Swiokla, Juliana, Lee, Yeon Sun, Zalevsky, Jonathan, Porreca, Frank. 2020. Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents. In Cellular and molecular neurobiology, 41, 949-960. doi:10.1007/s10571-020-00816-3. https://pubmed.ncbi.nlm.nih.gov/32107752/

9. Miyazaki, Takahiro, Choi, Irene Y, Rubas, Werner, Zalevsky, Jonathan, Doberstein, Stephen K. 2017. NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential. In The Journal of pharmacology and experimental therapeutics, 363, 104-113. doi:10.1124/jpet.117.243030. https://pubmed.ncbi.nlm.nih.gov/28778859/